J&J settles Amgen clash over psoriasis drug

Amgen can market a biosimilar version of Stelara from January 2025 after J&J resolved its infringement lawsuit that centred on two Stelara patents.

Fed Circ refutes Medtronic challenge

A prior art reference does not qualify, says the Federal Circuit, dashing the firm’s hope to invalidate five catheter technology patents.

Effects of GSK v Teva ripple as SCOTUS denies cert

Lawyers from Axinn, Veltrop & Harkrider explore a case that could have major implications for generic drugs, biosimilars, and how skinny labels are read.

Sanofi v Amgen antibody case lands front of queue at UPC

Sanofi v Amgen antibody case lands front of queue at UPC

Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.

More features

Latest news

Cooley appoints ‘first-rate’ life sciences partner trio

06-06-2023

The ‘formidable’ three bring 52 years’ experience from Fish & Richardson collectively | ‘Extensive’ patent trial background includes branded Hatch-Waxman litigation.

Indivior avoids multi-state antitrust trial with $100m payout

06-06-2023

Abbott sues former employee for alleged trade secrets theft

01-06-2023

‘A new dawn for patents’: the UPC opens its doors

01-06-2023

Moderna and Pfizer face fresh suits over COVID-19 vaccine

30-05-2023

UPC releases contingency plan for hard copy opt-outs

30-05-2023

More news

Regions

Sectors

LSIPR